An interventional study of LC + LCBDE + ENBD + primary closure of CBD and ERCP technique + LC in Common Bile Duct Stone, sponsored by Tongji Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-03-01.
Sponsored by Tongji Hospital · Not applicable, Interventional, and Treatment
Among 38 studies in Gallstones with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Gallstones · China.
Among the 38 studies in Gallstones with a site in China, this one is the 7th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2018, is one of 22 with no phase, and was the 12th registered.
200 studies on the registry are indexed under Gallstones; 36 are open to participants now.
Browse Gallstones studies →7 of the 38 studies in Gallstones with a site in China are open now. Recruiting first, the newest first:
Zhejiang University · Sites in China
Ages 18–65 · Women only
Chinese University of Hong Kong · Sites in China
Ages 18–80
Hepatopancreatobiliary Surgery Institute of Gansu Province · Sites in China
Ages 18–70
Shandong Linglong Yingcheng Hospital · Sites in China
Ages 20–60
Air Force Military Medical University, China · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 24 Gallstones studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 2 · Phase 4 3
First in 2005; this study’s year is marked. 3 started in 2018.
This study's planned enrollment of 200 is above the median of 98 across 121 interventional studies indexed under Gallstones.
Median enrollment 145 across the 28 interventional studies, 260 across the 10 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 38 have an industry lead sponsor. The 10 most frequent:
Tongji Hospital is the lead sponsor of 387 studies on the registry; 210 are open to participants now.
Tongji Hospital has 2 studies filed under Gallstones — fewer than ten, so there is no comparison to draw.
6 of the studies in Gallstones with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07368335The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolEfficacy and Safety of a Novel ERCP Robot in the Treatment of Common Bile Duct Stone | 2026-12-01 |
| NCT06699030Hepatopancreatobiliary Surgery Institute of Gansu ProvinceA Strategy for Gallstone Expulsion Through Dietary Therapy | 2026-12-01 |
| NCT06011941Peking University Third HospitalModified Laparoscopic Transcystic Biliary Drainage in the Management of Cholecystocholedocholithiasis | 2026-12-31 |
| NCT07522385Tongji HospitalA Study on the Efficacy and Safety of Endoscopic Ultrasound-guided Gastro-/Duodeno-cholecystostomy for the Treatment of Gallstones. | 2027-01-20 |
| NCT06926374Chinese University of Hong KongProspective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery | 2027-04 |
Add all 6 to your calendar (.ics) → With an account.
Among the 38 studies in Gallstones with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ABSTRACT Introduction: Common bile duct (CBD) stone is a common clinical situation, especially in Asia area. Laparotomy and laparoscopic surgical procedure are often used for treatment. This study compares outcomes of different surgical procedures treating for the disease.
Methods/design: This is a prospective, randomized, controlled multicenter trial with three treatment arms. One group underwent laparoscopic cholecystectomy (LC) + laparoscopic CBD exploration (LCBDE) + intraoperative endoscopic nasobiliary drainage ENBD + primary closure of CBD. The other underwent preoperative endoscopic retrograde cholangiopancreatography (ERCP) and subsequent LC and the third arm underwent laparoscopic cholecystectomy (LC) + laparoscopic CBD exploration (LCBDE) + primary closure of CBD. The duration of the entire trial is two years including prearrangement, follow-up and analyses.
Discussion: Despite the fact plenty evidences provided by meta-analyses suggests that these approaches would appear comparable. It is hopeful to fully address which would be the better approach with this RCT design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Procedure: LC + LCBDE + ENBD + primary closure of CBD
Procedure: ERCP technique + LC
Procedure: LC + LCBDE + primary closure of CBD
LC + LCBDE + ENBD + primary closure of CBD
ERCP technique + LC
LC + LCBDE + primary closure of CBD
Rate of Adverse outcomes
The patients developing complications/ the total patients
Time frame: 24 months
Plan to share: Yes
No publications or documents are linked to this record.
Start is estimated for Mar 2018; primary completion for Mar 2020, 24 months later.
Of 58 non-industry interventional studies with no phase under Gallstones, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 24 months is above that.
Counting every sponsor, half of 58 studies reached it within 20 months; a quarter within 12 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.